Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies

计划入组 56 人 · 首次发布于 2025 年 12 月 31 日

Selecting the SSV-1 as LIV in Scheuermann's Kyphosis

计划入组 74 人 · 首次发布于 2023 年 7 月 20 日

SoSu-liv. Mobile Media for Health Promotion

计划入组 566 人 · 首次发布于 2015 年 5 月 8 日

LIV-1 targeting exatecan antibody-drug conjugate (Triple-negative breast cancer, solid tumor)

anti-Liv-1 mAb/topoisomerase I Inhibitor ADC (Triple-negative breast cancer/solid tumor)

LIV-001

LIV CELL RTS 07DEC

NHI-1

United States

Xi'an No.1 Hospital

China

Computational pipeline uncovers subtype-specific ADC targets for cervical cancer

Vienna's VALANX Biotech Secures €3 Million to Advance Precision ADC Platform for Triple-Negative Breast Cancer

Radiopharmaceutical Antibody-Drug Conjugates (rADCs) Emerge as Promising Cancer Therapies